148.00 +0.43 (0.29%)
After hours: 7:51PM EDT
|Bid||140.47 x 1100|
|Ask||152.87 x 900|
|Day's Range||144.77 - 149.61|
|52 Week Range||92.33 - 157.50|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||162.73|
Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters. Abbott executives said the increase in manufacturing capacity will begin in the second half of this year and make room for the expected U.S. launch of the FreeStyle Libre 2. Abbott's plans for Libre, its fastest-growing diabetes product, used by 1.5 million people worldwide, will be in focus when the company reports quarterly earnings on Wednesday.
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
President, CEO and Chairman of Dexcom Inc (NASDAQ:DXCM) Kevin R Sayer sold 6,000 shares of DXCM on 07/08/2019 at an average price of $146.25 a share.
The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.
DexCom, Inc. today announced that it plans to release its second quarter 2019 financial results after market close on Wednesday, July 31, 2019. Management will hold a conference call to review the company's second quarter 2019 performance starting at 4:30 p.m.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Dexcom is the IBD Stock Of The Day as the medical devices company flirts with a breakout on its tenth straight day of gains. Shares broke out above a buy point briefly and could try again.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
Altair Engineering, Netgear, Fitbit, Microsoft and DexCom highlighted as Zacks Bull and Bear of the Day
For his "Executive Decision" segment of Mad Money Thursday night, Jim Cramer spoke with Kevin Sayer, chairman, president and CEO of Dexcom Inc. The trend-following Moving Average Convergence Divergence (MACD) oscillator just moved above the zero line for an outright buy signal on this time frame.
Dexcom Inc NASDAQ/NGS:DXCMView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for DXCM with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold DXCM had net inflows of $1.27 billion over the last one-month. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
DexCom, Inc. (DXCM) and Companion Medical, Inc. today announced a collaboration to enable a direct exchange of CGM data from Dexcom with insulin data from InPen™ into both companies’ software applications. This agreement is the first of its kind and paves the way for advanced diabetes decision support, an important tool for insulin users. Dexcom and Companion Medical are working together to develop a seamless data transfer of both insulin and glucose information.
While DexCom, Inc. (NASDAQ:DXCM) shareholders are probably generally happy, the stock hasn't had particularly good run...
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.